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The millennium development goals adopted in 2000 laid down
a core development agenda to which key international partners
have since closely adhered, while a special session of the UN
General Assembly held in 2001 on HIV/AIDS paved the way
for a large and sustained international response to that emerging
epidemic.1 Ten years on, high level delegates recently attended
a second special session of the UNGeneral Assembly on health,
this time to discuss what to do about the rising epidemic of
non-communicable diseases (NCDs) and how to integrate them
into future development activities.2
A key issue for debate—both for delegates at the summit and
for subsequent roll-out by countries—concerns the policies and
strategies that could or should form the backbone of a renewed
commitment to tackling non-communicable disease. Several
criteria influence the selection of global or national strategies
for prevention and control, including the current and projected
burden of disease, cost effectiveness, fairness, and feasibility
of implementing interventions, and political considerations.We
have conducted a series of analyses focusing on cost
effectiveness of interventions (see bmj.com).3-8 Here we draw
together our findings with a view to identifying those strategies
that offer the best value for money in tackling
non-communicable diseases and injury in low income settings.
The analyses complement an earlier BMJ series on the cost
effectiveness of interventions focused on attainment of the
millennium development goals.9
Comparative analysis of value for money
in health
We have assessed the costs and effects of over 500 single or
combined interventions for the prevention and control of
non-communicable diseases and injuries in countries in
sub-Saharan Africa and South East Asia that have high adult
and child mortality. We have considered most of the leading
contributors to this burden10: cardiovascular disease and
diabetes,3 chronic respiratory diseases,4 cancer,5 sensory loss
disorders,6 mental disorders 7 and road traffic injury.8
We used a generalised approach to estimating costs and
modelling health effects; this has its strengths as well as
limitations (box). On the cost side, we identified and measured
resources used to provide an intervention then multiplied them
by their respective price or unit cost; monetary values are
expressed in international dollars ($Int), which takes into
account inter-regional differences in purchasing power (in the
two resource settings considered here, one international dollar
is around $0.32-$0.44; £0.21-£0.28; €0.25-€0.34). On the effect
side, health gains at the population level are expressed in terms
of disability adjusted life years (DALYs) averted, a measure
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that takes into account the effects on both mortality and
morbidity.
When trawling through so many intervention strategies, how
should we determine whether an intervention is cost effective?
We defined an intervention as “highly cost effective” if the cost
of generating an extra year of healthy life (equivalent to averting
one DALY) was below the average annual income or gross
domestic product (GDP) per person—that is, $Int2000 in the
two geographical sub-regions considered here. Interventions
that produce a healthy life year for more than three times GDP
per person ($Int 6000) are considered “not cost-effective,” and
those in-between are considered cost effective. These thresholds
are based on a recommendation of the WHO Commission on
Macroeconomics and Health11 and broadly coincide with the
thresholds used in several high income countries, including the
United States and United Kingdom.12
Priorities for intervention
The table⇓ provides an overview of the main individual and
population based health improvement strategies that we assessed,
grouped together into the analytical clusters or disease areas
that we used in our analyses.3-8 Interventions range from fiscal
or regulatory measures that target the adverse health
consequences of alcohol or tobacco use (such as increased taxes
or advertising bans) to complex treatment strategies targeted at
individuals with advanced stages of disease (including drug
treatment for congestive heart failure and surgery for cancer).
The cost, effect, and cost effectiveness of assessed interventions
in both regions varies by at least three orders of magnitude—for
example, the annual cost of implementing an intervention varies
from as little as a few cents to over $Int10 per capita, while the
annual health impact per million population ranges from 10 to
10 000 healthy life years (see bmj.com). Likewise, average cost
effectiveness ratios range from $Int14 to more than $Int1m (for
a fruit and vegetable subsidy programme aimed at reducing the
incidence of colorectal cancer). The median cost per health year
gained is $Int800-900. Results also vary between the two
regions, most notably because of differences in risky health
behaviours or rates of disease (for example, tobacco use and
heart disease are more prevalent in South East Asia than in
Africa).
By allowing all interventions to compete with each other for
available resources, we can identify a subset that is dominant
over the rest, starting with the single most cost effective option
and then adding in the next most cost effective until the budget
is used up (or until the value for money threshold is exceeded).
The sequential incremental cost effectiveness ratios for these
dominant interventions is listed in web appendix 2 (see
bmj.com). Figures 1⇓ and 2⇓ show the most cost effective
interventions grouped by disease or injury cluster for each region
to illustrate how resources might be allocated within and across
them.
Do some health conditions fare better
than others?
Results for each of the disease clusters are discussed in greater
detail in the accompanying research studies.3-8 If we look across
them all we can see that almost all clusters have several
interventions that are highly cost effective (that is, cost per
DALY avoided is less than $Int2000); the exception is
respiratory disorders, for which the most cost effective
intervention is just over this threshold (low dose inhaled
corticosteroids for mild asthma). So if decision makers in these
resource settings accept this cost effectiveness threshold, these
competing public health priority areas can all make some
legitimate claim for scarce resources on economic efficiency
grounds. If on the other hand decision makers were to use a
threshold of only $Int100 per DALY saved—a level proposed
in the 1993 World Development Report, for example13
—virtually all of the interventions considered would not qualify
for funding.
In terms of value for money, health conditions that are often
left out of priority lists or action plans (such as sensory loss or
mental disorders) have as much a case for funding as do cancer,
cardiovascular disease, or diabetes.13 For example, antibiotic
treatment of chronic otitis media (a persistent inflammation of
the middle ear) is the most cost effective intervention in the two
regions (< $Int100/DALY saved), while extraction of cataracts
and proactive screening for hearing loss are among the biggest
potential contributors to population health gain.
Another striking observation is the degree of variation within
health conditions. While some interventions offer very good
value for money—drug treatment for hypertension, tobacco
control measures, and epilepsy treatment, to name just a
few—others within the same cluster do not. This is well
illustrated by cancer interventions, where cost effectiveness
ranges from a few hundred international dollars per DALY
saved (for cervical cancer screening or lesion removal as
required) to tens of thousands (such as some of the combined
screening and treatment strategies for cervical and colorectal
cancer). Other examples of interventions that are relatively cost
ineffective include the use of newer antipsychotic drugs for
schizophrenia and the treatment of advanced stages of chronic
obstructive pulmonary disease. This points to the importance
of carefully evaluating and choosing an appropriate set of
interventions for scaled-up investment and implementation;
selecting an inefficient set will waste money and limit potential
health gains.14
Is prevention better than treatment?
It is often asserted that preventing disease will be a better bet
than treating it after it has occurred. Our regional cost
effectiveness analyses—together with the findings of Salomon
et al in relation to care and prevention of non-communicable
diseases in Mexico15—show that population based preventive
strategies do not clearly win out against more individual based
interventions, implying that a multifaceted and balanced
approach to the burden of non-communicable disease and injury
is required. Furthermore, although the estimated cost of many
preventive strategies is low (<$Int0.50 per capita)—particularly
mass media and fiscal or regulatory measures that require no
healthcare resources—others are very expensive. For example,
annual screening of schoolchildren and adults for hearing loss
is estimated to cost more than $Int10 per person, and multidrug
therapy for people with at least a 5% risk of a cardiovascular
disease event over the next 10 years would cost over $Int2.50
per capita.
Conclusion
Through our analyses we have attempted to better understand
the expected health effect and cost of a wide array of
interventions that could be introduced or scaled up to combat
the challenge of non-communicable diseases and injury in
developing regions of the world. Although costs and effects
vary substantially, there is a subset of interventions for all the
health categories considered that offers good value for money
and can form the basis of an evidence based and integrated
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Box: Strengths and limitations of generalised cost effectiveness analysis
Strengths
• Use of a consistent method enables genuine like-with-like comparisons to be made across disease entities and resource settings
• Comparing costs and effects against no intervention overcomes the problem of varying levels of current coverage between countries
• Where applicable, target coverage rates are allowed to vary so that efficiencies associated with economies of scale and scope can
be identified (eg, the cost of reaching the most isolated segments of the population may well involve some loss in efficiency)
• Where strategies are combined, account is taken of the interactions between them (including shared costs and joint effects).
Limitations
• Can provide only a broad indication of value for money in health and overlooks the diversity or specificity of individual country contexts
• Extrapolation of best available international evidence—often from higher to lower income resource settings—may overestimate or
underestimate the costs and effects of interventions (especially those with a behavioural dimension)
• The focus on health outcomes means that broader welfare consequences such as improved production or reduced property damage
are not taken into account
• Coverage of disease conditions and interventions is incomplete and influenced by the availability of data (eg on musculoskeletal
disorders and prevention of diabetes)
response. Some results are similar to those of previous
analyses,16 17 but we have included previously under-researched
areas of economic evaluation (such as sensory loss disorder and
road traffic injury) and are able to base our findings on validated
and consistent methods. That said, our approach has some
limitations, and gaps in our knowledge base remain (box). These
gaps can be closed through the further development and
application of economic modelling studies. Country level
contextualisation studies—as carried out in Mexico, Estonia,
Nigeria, and Vietnam, for example15 18-20—are a worthwhile if
resource intensive means of incorporating local priorities, health
system characteristics, and data into the evaluative process.21
A final point is that efficiency represents but one of many
criteria that need to be taken into account when allocating
resources or determining priorities. In particular, efficient
allocation of resources may not be fair. For example, treatment
of schizophrenia may not be one of the most cost effective
options, but withholding effective care for this severe,
debilitating condition is likely to be considered highly unjust.
This speaks to the need for careful and inclusive deliberation
about how to develop health systems in a way that ensures not
only good value for money but also equal access and financial
protection for those in need (including poor and vulnerable
people).
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Table
Table 1| Categorisation of intervention strategies assessed3-8
Main intervention strategies
Health conditionsCluster IndividualPopulation
Mastectomy, radiotherapy, chemotherapyBiannual mammographic screeningBreast cancerCancer
Lesion removal, radiotherapy, chemotherapy, surgeryScreening (VIA, smear test); HPV vaccinationCervical cancer
Polyps/lesion removal, radiotherapy, chemotherapy,
surgery
Screening (faecal occult blood testing,
colonoscopy)
Colorectal cancer
Blood pressure and cholesterol lowering drugs,
combined drug therapy for those at high risk
Reduced dietary salt (regulated food industry),
mass media campaigns to reduce cholesterol
Hypertension and cholesterolaemiaCardiovascular
disease
Single or combined drug regimens for
acute and post-acute heart disease and stroke
Ischaemic heart disease and stroke
Glycaemic control, retinopathy/neuropathy screening
and treatment
Diabetes mellitus
Nicotine replacement, counsellingExcise taxes, advertising bans; indoor air lawsTobacco use
Inhaled bronchodilators and corticosteroids, smoking





Antibiotic treatment. trichiasis surgery, cataract
extraction
Active and passive screening strategiesTrachoma; cataract; refractive error;
hearing loss; chronic otitis media
Sensory loss
disorders
Psychoactive drugs, psychosocial therapiesPsychotic and affective disordersMental disorders
Antiepileptic drugsEpilepsy
Brief physician adviceExcise taxes, advertising bans, restricted
access
Hazardous alcohol use
Enforcement of drink-driving laws, speed
limits, seat belt use, helmet use
Road traffic injuryInjury
VIA= visual inspection with acetic acid; HPV=human papillomovirus.
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Figures
Fig 1 Incremental cost effectiveness ($Int/DALY saved) of dominant interventions in sub-Saharan African countries with
high child and adult mortality (HPV=human papillomavirus, VIA= visual inspection with acetic acid, IHD=ischaemic heart
disease, CHF=chronic heart failure, FOB=faecal occult blood)
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Fig 2 Incremental cost effectiveness ($Int/DALY saved) of dominant interventions in South East Asian countries with high
child and adult mortality (HPV=human papillomavirus, VIA= visual inspection with acetic acid, IHD=ischaemic heart disease,
CHF=chronic heart failure, FOB=faecal occult blood)
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